|
|
|
|
Posaconazole Compares With Standard Onchomycosis Treatments: Presented at AAD
-- The antifungal posaconazole appears to combat onchomycosis as well as standard treatments and better than placebo, researchers said here at the 68th Annual Meeting of the American Academy of Dermatology (AAD).More than half of the patients in the study...
|
|
|
Pacific Communications Named Agency of Record for SANCTURA XR from Allergan, Inc
Pacific Communications announced that they have been chosen as Agency of Record for SANCTURA XR, a QD treatment for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.This review...
|
|
|
Pharmacokinetics: Scientists at Astellas Pharma, Inc. detail research in pharmacokinetics
Today's Medical & Research News Pharmacokinetics Scientists at Astellas Pharma, Inc.detail research in pharmacokinetics March 10th, 2010 Printer-Friendly Version City:Kashima Country:Japan Adjuvant Anesthetic Antianxiety Drug Development Drugs GABA...
|
|
|
Insulin Glargine QD Equivalent to Insulin Detemir BID for Type 2 Diabetics
_ Insulin Glargine QD Equivalent to Insulin Detemir BID for Type 2 Diabetics.
|
|
|
Insulin Glargine QD Equivalent to Insulin Detemir BID for Type 2 Diabetics
Once-daily insulin glargine and twice-daily insulin detemir provided similar gly Insulin Glargine QD Equivalent to Insulin Detemir BID for Type 2 Diabetics.
|
|
|
Insulin glargine QD equivalent to insulin detemir BID for type 2 diabetics
Clinical Last Updated: 2010-03-08 17:09:15 -0400 (Reuters Health) By Will Boggs, MD NEW YORK (Reuters Health) - Once-daily insulin glargine and twice-daily insulin detemir provided similar glycemic control for insulin-nave type 2 diabetics in a noninferiority...
|
|
|
Enanta Hcv Programs
Enanta has developed significant expertise and know-how in the field of HCV protease inhibitors.The Company has established an SAR strategy to create novel and proprietary series and leads that demonstrate significant anti-viral potency in the enzyme and...
|
|
|
Large-Scale Application of 'Deep' Sequencing Using 454 Technology to HIV Tropism Screening
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin 17th CROI 2010 Feb 16-19 SF Luke C Swenson1, Winnie Dong1, Theresa Mo1, Alexander Thielen2, Mark Jensen3, Doug Chapman4, Ian James5,...
|
|
|
Antares Pharma completes enrollment in Phase III overactive bladder trial
(Datamonitor via COMTEX) Antares Pharma has completed patient enrollment in the double-blind portion of the company's Phase III clinical trial of Anturol, its transdermal oxybutynin ATD gel for the treatment of overactive bladder, or OAB.The randomized,...
|
|
|
Once-Daily Delayed-Release Mesalamine as Effective as Twice-Daily Dosing in Maintenance of Remission for Patie
-- For more than 5 decades now, the mainstay of treatment for ulcerative colitis (UC) has been 5-aminosalicylic acid, taken twice daily.However, a newly released study has reported that the same daily amount of the drug, taken at 1 time in 400-mg delayed...
|
|
|
Multifunctional Fe3O4 Cored Magnetic-Quantum Dot Fluorescent Nanocomposites for RF Nanohyperthermia of Cancer Cells
Highly biocompatible luminescent superparamagnetic nanocomposites have been synthesized from Fe3O4/SiO2?QDs (IQ).Fe3O4 nanoparticles coated with a silica shell, Fe3O4/SiO2 (IOS), and water-soluble CdSe?ZnS quantum dots (QDs) were assembled together by...
|
|
|
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
Objectives: To evaluate the 2-year safety and efficacy of adding sitagliptin or glipizide to ongoing metformin in patients with type 2 diabetes.Methods: Patients who were on a stable dose of metformin ([ge] 1500 mg/day) for at least 8 weeks were randomised in a...
|
|
|
Antares Pharma completes enrollment in Phase III overactive bladder trial
Antares Pharma has completed patient enrollment in the double-blind portion of the company's Phase III clinical trial of Anturol, its transdermal oxybutynin ATD gel for the treatment of overactive bladder, or OAB.The randomized, double-blind, parallel,...
|
|
|
Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol For The Treatmen
Antares Pharma, Inc.(NYSE Amex: AIS) announced that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol, its transdermal oxybutynin ATD gel for the treatment of overactive bladder (OAB). Top line data...
|
|
|
Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol For The Treatment Of Overactive Bladder
Antares Pharma, Inc.(NYSE Amex: AIS) announced that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol, its transdermal oxybutynin ATD gel for the treatment of overactive bladder (OAB). Top line data...
|
|
|
Asenapine as Effective as Olanzapine for Long-Term Treatment of Patients With Bipolar Disorder: Presented at E
-- Asenapine remained effective throughout 52 weeks of exposure in patients with mania associated bipolar I disorder, according to study results presented here on March 1 at the European Psychiatric Association (EPA) 18th European Congress of Psychiatry.The...
|
|
|
Once-Daily Delayed-Release Mesalamine as Effective as Twice-Daily Dosing in Maintenance of Remission for Patie
-- For more than 5 decades now, the mainstay of treatment for ulcerative colitis (UC) has been 5-aminosalicylic acid, taken twice daily.However, a newly released study has reported that the same daily amount of the drug, taken at 1 time in 400-mg delayed...
|
|
|
Axon expands in the US
Surrey, UK-based Axon Communications has appointed Mario Nacinovich as managing director of its new US operations.Nacinovich will be based in New York and will report to Ralph Sutton, the healthcare consulting firms managing partner who is based in London.
|
|
|
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatmen
-- On Track for New Drug Application Filing in 2010 -- EWING, N.J.--(BUSINESS WIRE)--Mar 2, 2010 - Antares Pharma, Inc.(NYSE Amex: AIS) announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of...
|
|
|
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol? for the Treatme
EWING, N.J.(BUSINESS WIRE) Antares Pharma, Inc.(NYSE Amex: AIS) announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol?, its transdermal oxybutynin ATD? gel for the treatment of...
|
|
|
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
CAMBRIDGE, Mass., Feb.25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial...
|
|
|
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatmen
-- On Track for New Drug Application Filing in 2010 -- Dr.Paul Wotton, President and Chief Executive Officer of Antares, said, We are delighted to announce the completion of enrollment for this pivotal trial of Anturol, and we remain on track to file a New...
|
|
|
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatment of Overactive Bladder
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc.(NYSE Amex: AIS) announced today that it has completed enrollment in the double-blind portion of the Company?s Phase 3 clinical trial of Anturol?, its transdermal oxybutynin ATD? gel for the treatment of...
|
|
|
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatment of Overactive Bladder
Companies mentioned in this article: Antares Pharma, Inc.EWING, N.J. -- (BUSINESS WIRE) -- Antares Pharma, Inc. (NYSE Amex: AIS) announced today that it has completed enrollment in the double-blind portion of the Companys Phase 3 clinical trial of...
|
|
|
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatment of Overactive Bladder ..
Antares Pharma, Inc.(NYSE Amex: AIS) announced today that it has completed enrollment in the double-blind portion of the Companys Phase 3 clinical trial of Anturol, its transdermal oxybutynin ATD gel for the treatment of overactive bladder (OAB). Top line...
|
